Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 809 results for "novartis ag"

Novartis PKC412 (midostaurin) pivotal data published in NEJM show 60% response rate in advanced systemic masto...
TeleTrader.com

NOVARTIS : PKC412 (midostaurin) pivotal data published in NEJM...

Novartis International AG / Novartis PKC412 (midostaurin) pivotal data published in NEJM show 60% response rate in advanced systemic mastocytosis (SM) . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible ... 4 Traders, 17 hours ago
[x]  

50 images for novartis ag

Share Market Updates, 1 week ago
Octafinance, 6 days ago
Drug Development Technology, 1 month ago
Business Insider, 1 month ago
Business Insider, 1 month ago
Reuters India, 1 month ago
China Post, 3 weeks ago
MyNewsDesk, 1 month ago
Schaeffers Research, 1 month ago
Channel NewsAsia, 1 month ago

First Circuit Upholds Dismissal of FCA Claims with Prejudice Taking Middle-Ground Approach to Particularity Requirement

The First Circuit, in United States ex rel. Garcia v. Novartis AG , upheld the dismissal of a FCA claim with prejudice against Novartis Pharmaceutical Corporation, Novartis Corporation, Genentech, Inc. and Roche Holdings, Inc. (collectively ...
 Lexology20 hours ago
MyNewsDesk

Global Anaplastic Oligoastrocytoma Pipeline Report 2016 Featuring Axelar, Cavion, Celldex Therapeutics, e-Therapeutics, Novartis & Pfizer - Research and Markets

DUBLIN--(Business Wire)-- Research and Markets has announced the addition of the "Anaplastic Oligoastrocytoma - Pipeline Review, H1 2016" report to their offering. This report provides comprehensive information on the therapeutic development for ...
 Digital Journal19 hours ago Global Non-Hodgkin Lymphoma Pipeline Review, H1 2016 - Analysis, Technologies & Forecasts - Key Vendors: 4SC, Merck, Novartis - Research and Markets  Digital Journal1 day ago Cytochrome P450 11B2 Mitochondrial Pipeline Review, H1 2016 Featuring Angion Biomedica Corp, Merck & Co., & Novartis AG - Research and Markets  4 Traders1 week ago Global Meningioma Pipeline Report 2016 - Therapeutics Review of 8 Companies & Drug Profiles - Research and Markets  Minyanville3 hours ago
[x]  
Zacks.com

Xencor Stock Up On Cancer Drugs Partnership with Novartis

Shares of Xencor, Inc . XNCR rallied 32.06% after the company announced that it has entered into a collaboration and license agreement with Swiss major, Novartis AG NVS . Terms of the Agreement As per the agreement terms, the companies will ...
 Zacks.com15 hours ago Xencor, Inc. (XNCR) Rockets on Licensing Deal With Novartis AG (NVS)  InvestorGuide.com23 hours ago Novartis AG Taps Xencor's Bispecifics Expertise in $150 Million Immuno-Oncology Deal  BioSpace2 days ago Xencor, Novartis In Collaboration, License Deal For Bispecific Antibodies  Quotenet.com2 days ago
[x]  

Mid-Afternoon Market Update: Crude Oil Up 2.5%; Xencor Shares Surge Following Deal With Novartis

Toward the end of trading Tuesday, the Dow traded up 0.82 percent to 17,281.21 while the NASDAQ climbed 1.44 percent to 4,660.74. The S&P also rose, gaining 0.96 percent to 2,019.82. Leading and Lagging Sectors On Tuesday, energy shares rose ...
 Benzinga.com1 day ago

BRIEF-Sandoz Canada says Health Canada to review cos regulatory submission

June 28 Novartis Ag * Sandoz Canada says Health Canada accepted for review co's regulatory submission for subsequent entry biologic version of etanercept Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780) ...
 Reuters UK2 days ago Sandoz Canada Regulatory Submission for Subsequent Entry Biologic Etanercept Accepted for Review by Health Canada  Minyanville2 days ago Sandoz Canada Launches First Non-Prescription Naloxone Approved by Health Canada for Treating Opioid Overdoses  BioMedReports6 days ago
[x]  
Octafinance

Novartis AG (NVS) Stock Rating Upgraded by TheStreet

Novartis AG (NYSE:NVS) was upgraded by equities researchers at TheStreet from a hold rating to a buy rating in a research report issued on Friday. Several other research firms have also recently issued reports on NVS. Citigroup Inc. cut Novartis AG ...
 SleekMoney1 day ago Novartis AG (NVS) Upgraded to Buy at TheStreet  American Banking News - Forex1 day ago Novartis AG (NVS) Raised to Buy at TheStreet  American Banking News1 day ago Novartis AG (NVS) Upgraded at TheStreet  Mideast Time7 hours ago
[x]  

BRIEF-Novartis, Roche say too early to predict impact of Brexit vote

June 24 (Reuters) - * Roche Holding Ag says key priority is to ensure that UK environment continues to support scientific innovation and speedy access of innovative medicines for patients * Roche says too early to comment on the potential ...
 Reuters UK6 days ago

BRIEF-Ophthotech says achieved $30 mln enrollment milestone from Novartis Pharma

June 20 Ophthotech * Says has achieved a $30 million enrollment milestone from novartis pharma ag as part of ex-us licensing * Expects to announce initial, topline data from two studies in q4 of this year * Says expects to announce ...
 Reuters UK1 week ago

Rigel, Novartis to Collaborate on Five Drug Discovery Projects

Rigel Inc. (South San Francisco) and Novartis Pharma AG (Basel, Switzerland) will work together on five different five-year research projects to identify targets for products that can treat, prevent, or diagnose the effects of disease using Rigel's ...
 Drug Discovery Online2 weeks ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - novartis ag
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less